21 September 2024 v2024.58.1 limited_company_frs_102_section_1a_v1_1_2 companies_houseSoftwarefalsetruetruetrueNo description of principal activity00falsexbrli:purexbrli:sharesiso4217:GBP156905592024-09-212024-11-18156905592024-11-1815690559bus:Director12024-09-212024-11-1815690559bus:RegisteredOffice2024-09-212024-11-18156905592024-04-292024-09-2015690559core:WithinOneYear2024-09-20156905592024-09-2015690559core:ShareCapital2024-11-1815690559core:ShareCapital2024-09-2015690559core:RetainedEarningsAccumulatedLosses2024-11-1815690559core:RetainedEarningsAccumulatedLosses2024-09-2015690559core:RetainedEarningsAccumulatedLosses2024-04-292024-09-2015690559core:ShareCapital2024-04-292024-09-2015690559core:ShareCapital2024-09-2115690559core:RetainedEarningsAccumulatedLosses2024-09-21156905592024-09-2115690559core:ShareCapital2024-09-212024-11-181569055912024-09-212024-11-1815690559countries:EnglandWales2024-09-212024-11-1815690559bus:AuditExemptWithAccountantsReport2024-09-212024-11-1815690559bus:PrivateLimitedCompanyLtd2024-09-212024-11-1815690559bus:SmallEntities2024-09-212024-11-1815690559bus:FullAccounts2024-09-212024-11-18
Company registration number:
15690559
CystemCycle Limited
Unaudited Financial Statements for the period ended
18 November 2024
CystemCycle Limited
Officers and Professional Advisers
Period ended
18 November 2024
Director
Mr A Jones
Registered office
82a James Carter Road
Mildenhall
IP28 7DE
United Kingdom
Accountant
Theatrico Limited
Lower Flat, Stratford House
Kingham Hill, Kingham
Chipping Norton
Oxfordshire
OX7 6TE
United Kingdom
Bank
NatWest
18 High Street
Newmarket
CB8 8LH
United Kingdom
CystemCycle Limited
Director's Report
Period ended
18 November 2024
The director presents the report and the unaudited
financial statements
of the company for the period from 21 September 2024 to 18 November 2024.

Directors

The director who served the company during the period was as follows:
Mr A Jones

Principal Activities

The company did not trade during this accounting period, and only issued share capital to cover the company's liabilities in preparation for strike-off.

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on
16 November 2024
and signed on behalf of the board by:
Mr A Jones
Director
CystemCycle Limited
Report to the board of directors on the preparation of the unaudited statutory financial statements of CystemCycle Limited
Period ended
18 November 2024
As described on the statement of financial position, the Board of Directors of
CystemCycle Limited
are responsible for the preparation of the
financial statements
for the period ended
18 November 2024
, which comprise the income statement, statement of financial position, statement of changes in equity and related notes.
You consider that the company is exempt from an audit under the Companies Act 2006.
In accordance with your instructions we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.
Theatrico Limited
Lower Flat, Stratford House
Kingham Hill, Kingham
Chipping Norton
Oxfordshire
OX7 6TE
United Kingdom
Date:
18 November 2024
CystemCycle Limited
Income Statement
Period ended
18 November 2024
Period from 21 Sep 2024 to 18 Nov 2024Period from 29 Apr 2024 to 20 Sep 2024
££
Turnover -  
10,141
 
Cost of sales -   (9,944 )
Gross profit -  
197
 
Administrative expenses -  
(1,014
)
Operating loss -  
(817
)
Loss before tax -  
(817
)
Tax on loss -   -  
Loss for the financial period -  
(817
)
The company has no other recognised items of income or expense other than the results for the period as set out above.
CystemCycle Limited
Statement of Financial Position
18 November 2024
18 Nov 202420 Sep 2024
Note££
Creditors: amounts falling due within one year 5 -  
(816
)
Net current liabilities -  
(816
)
Total assets less current liabilities -   (816 )
Capital and reserves    
Called up share capital
817
 
1
 
Profit and loss account
(817
)
(817
)
Shareholders deficit -  
(816
)
For the period ending
18 November 2024
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
  • The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476;
  • The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These
financial statements
have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
These
financial statements
were approved by the board of directors and authorised for issue on
16 November 2024
, and are signed on behalf of the board by:
Mr A Jones
Director
Company registration number:
15690559
CystemCycle Limited
Statement of Changes in Equity
Period ended
18 November 2024
Called up share capitalProfit and loss accountTotal
£££
At 29 April 2024 -   -   -  
Loss for the period- (817)(817)
Total comprehensive income for the period- 
(817
)
(817
)
Issue of shares
1
 - 
1
 
Total investments by and distributions to owners
1
 - 
1
 
At 20 September 2024 and 
21 September 2024
1
 
(817
)
(816
)
Profit for the period- - - 
Total comprehensive income for the period- - - 
Issue of bonus shares
816
 - 
816
 
Total investments by and distributions to owners
816
 - 
816
 
At
18 November 2024
817
 
(817
)- 
CystemCycle Limited
Notes to the Financial Statements
Period ended
18 November 2024

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
82a James Carter Road
,
Mildenhall
,
IP28 7DE
, United Kingdom.

2 Statement of compliance

These
financial statements
have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

Basis of preparation

The
financial statements
have been prepared on the historical cost basis, as modified by the revaluation of certain assets.
The
financial statements
are prepared in sterling, which is the functional currency of the company.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price and are subsequently measured as follows: Debt instruments are subsequently measured at amortised cost and commitments to receive a loan and to make a loan to another entity are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.
All other financial instruments, including derivatives, are initially recognised at fair value, which is normally the transaction price and are subsequently measured at fair value, with any changes recognised in profit or loss.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
All equity instruments regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.
Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4 Average number of employees

The average number of persons employed by the company during the period was Nil (2024: Nil).

5 Creditors: amounts falling due within one year

18 Nov 202420 Sep 2024
££
Trade creditors -  
816